Patents by Inventor Arnaldo Caruso

Arnaldo Caruso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210246456
    Abstract: A method of enhancing or inducing the expression of the HLA-G molecule by human cells is provided. The method includes administering the human Herpesvirus 6 U94 molecule or a derivative thereof, or a gene expression vector including and expressing the human Herpesvirus 6 U94 gene to a patient in need thereof or to an in vitro cell, tissue, or organ culture.
    Type: Application
    Filed: June 7, 2019
    Publication date: August 12, 2021
    Inventors: Arnaldo CARUSO, Roberta RIZZO, Dario DI LUCA, Elisabetta CASELLI, Francesca CACCURI
  • Publication number: 20160213651
    Abstract: The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 28, 2016
    Applicant: POLICHEM S.A.
    Inventors: Arnaldo Caruso, Simona Fiorentini
  • Patent number: 9090675
    Abstract: Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: July 28, 2015
    Assignee: Medestea Research & Production S.p.A.
    Inventors: Arnaldo Caruso, Giulia Federica Merizzi, Antonio Soleti
  • Publication number: 20140294941
    Abstract: There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 2, 2014
    Inventors: Arnaldo CARUSO, Dario Di Luca
  • Publication number: 20130028908
    Abstract: Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 31, 2013
    Applicant: Medestea Research & Production S.p.A.
    Inventors: Arnaldo Caruso, Giulia Federica Merizzi, Antonio Soleti
  • Publication number: 20110142918
    Abstract: There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.
    Type: Application
    Filed: June 10, 2009
    Publication date: June 16, 2011
    Applicant: PHOEBUS S.R.L.
    Inventors: Arnaldo Caruso, Dario Di Luca
  • Publication number: 20100158876
    Abstract: The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process.
    Type: Application
    Filed: October 28, 2009
    Publication date: June 24, 2010
    Inventors: Giulio ALESSANDRI, Arnaldo Caruso, Josè Sebastian Franzone
  • Patent number: 7541036
    Abstract: New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1 is an amino acid residue selected from Ser and Arg; X2 is an amino acid residue selected from Gly, Glu and Ser; X3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X5 is an amino acid residue selected from Lys, Arg and Ser; and X6 is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: June 2, 2009
    Assignee: Medestea Internazionale S.r.l.
    Inventors: Arnaldo Caruso, Jose Sebastian Franzone
  • Publication number: 20060110825
    Abstract: The invention relates to a process for the preparation of human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, bFGF, EGF, VEGF, LIF, heparin and usual inorganic salts, natural amino acids and vitamins necessary for the growth of mammalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue stem cells (hFSC) obtainable by this process.
    Type: Application
    Filed: April 9, 2003
    Publication date: May 25, 2006
    Inventors: Giulio Alessandri, Arnaldo Caruso, Jose Franzone
  • Publication number: 20040249124
    Abstract: New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1 is an amino acid residue selected from Ser and Arg; X2 is an amino acid residue selected from Gly, Glu and Ser; X3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X5 is an amino acid residue selected from Lys, Arg and Ser; and X6 is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
    Type: Application
    Filed: July 30, 2004
    Publication date: December 9, 2004
    Inventors: Arnaldo Caruso, Jose Sebastian Franzone